News for Radiopharmaceutical
It happens this was temporarily addressed in the latest Budget Bill passed by Congress. But, as with all legislation it’s not clear the extent of the benefit to hospital based providers of nuclear imaging services. In short those radiopharmaceuticals removed from the pass through category have increased reimbursement while the concurrent technical fee was reduced to result in a net zero affect on spending. These same items will revert back to their pass through status later this year and will not be changed until 2019, and then possibly not at all. CMS is studying the situation. Stay tuned.
Click here to read more.